An expanded access record providing Givosiran in Acute Hepatic Porphyria, sponsored by Alnylam Pharmaceuticals. Approved for marketing. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-20.
Sponsored by Alnylam Pharmaceuticals · Expanded access
The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.
33 studies on the registry are indexed under Porphyria, Erythropoietic; 1 is open to participants now.
Browse Porphyria, Erythropoietic studies →Alnylam Pharmaceuticals is the lead sponsor of 82 studies on the registry; 20 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 14 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Has any of the following laboratory parameter assessments at Screening:
givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
Also known as: ALN-AS1
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Porphyrias, Hepatic
Alnylam Pharmaceuticals